Compulsory licensing in Canada—revisited

On March 25, 2020, the government of Canada acted swiftly to enact legislation in response to COVID-19. The legislation, which was introduced into Parliament just the day before, brought sweeping changes to various aspects of Canadian law, including expanding the compulsory licensing framework in the Patent Act.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Takeda sees off UK challenge to Elvanse SPC

28 September 2026 Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision.

Pharma

Mylan throws down new gauntlet in Novo Wegovy patent fight

25 September 2026 Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.

Pharma

Novartis defeats Orange Book challenge but suffers EU setback

24 September 2026 An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.

More features

Takeda sees off UK challenge to Elvanse SPC

Conley Rose welcomes back former employee with legal and business nous

Mylan throws down new gauntlet in Novo Wegovy patent fight

Novartis defeats Orange Book challenge but suffers EU setback

Behind the case: How Novartis defended its blockbuster Entresto in the UK

Leading European patent litigator to join Carpmaels & Ransford

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Beyond the primary patent: How pharma can build competitive barriers

Compulsory licensing in Canada—revisited

More on this story

Editor's picks

Editor's picks

More features